Logo Image
NEWS
Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted Pulse
CONFERENCES
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
MEDIA
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPractice PlaybookShortsVideo Series
PUBLICATIONS
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
More
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
  • NEWS
  • CONFERENCES
  • MEDIA
  • PUBLICATIONS
  • CASE-BASED ROUNDTABLE
  • PARTNERS
  • RESOURCES
  • SUBSCRIBE
  • BRAIN CANCER
  • BREAST CANCER
    • HER2 Breast Cancer
  • COMMUNITY ONCOLOGY PRACTICE
  • GENITOURINARY CANCERS
    • Bladder Cancer
    • Prostate Cancer
    • Renal Cell Carcinoma
  • GENOMIC TESTING
    • Liquid Biopsies
  • GI CANCERS
    • Pancreatic Cancer
    • Colorectal Cancer
    • Gastric Cancer
    • GIST
    • HCC
  • GYNECOLOGIC CANCERS
    • Cervical Cancer
    • Endometrial Cancer
    • Ovarian Cancer
  • HEAD & NECK CANCERS
  • HEMATOLOGY
    • Bone Marrow & Stem Cell Transplant
  • IMMUNOTHERAPY
    • CAR T-Cell Therapy
  • LEUKEMIAS
    • AML
    • Chronic Lymphocytic Leukemia
    • Chronic Myeloid Leukemia
  • LUNG CANCER
    • MET-Targeted Therapy
    • Small Cell Lung Cancer
    • Biomarker-Driven Lung Cancer
    • EGFR+ Lung Cancer
  • LYMPHOMAS
    • DLBCL
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
  • MPNs
  • MULTIPLE MYELOMA
  • NTRK GENE FUSIONS
  • ONCOLOGY POLICY
  • SARCOMA
  • SKIN CANCERS
    • Melanoma
  • THYROID CANCERS
Spotlight -
Community Oncology Practice|
Oncology Policy|
Myeloma|
CLL|
Genomic Testing|
GU Cancers
Advertisement
Case Based Roundtable Logo

This roundtable series considers treatments for maintenance after first-line chemotherapy in patients with locally advanced or metastatic bladder cancer, as discussed by key opinion leaders at virtual live events and interviews.

  • ALL
  • BRAIN CANCER
  • BREAST CANCER
  • GENITOURINARY CANCERS
  • GI CANCERS
  • GYNECOLOGIC CANCERS
  • HCC
  • HEMATOLOGY
  • LEUKEMIAS
  • LUNG CANCER
  • LYMPHOMAS
  • MPNS
  • MULTIPLE MYELOMA
  • PROSTATE CANCER
  • RENAL CELL CARCINOMA
  • SKIN CANCERS
  • THYROID CANCERS

Maintenance Options in Patients With Bladder Cancer

Deciding Who Is Appropriate for Bladder Cancer Maintenance Therapy
Deciding Who Is Appropriate for Bladder Cancer Maintenance Therapy
November 06, 2025
Chandler H. Park, MD, discusses real-world data for maintenance avelumab in bladder cancer and factors that sway his treatment selection.
QOL and Survival Outcomes Favor Avelumab Maintenance in Bladder Cancer
QOL and Survival Outcomes Favor Avelumab Maintenance in Bladder Cancer
October 16, 2025
Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of avelumab as maintenance therapy for advanced bladder cancer.
Category 1 Choices Available for Metastatic Bladder Cancer
Category 1 Choices Available for Metastatic Bladder Cancer
October 03, 2025
Chandler H. Park, MD, discusses NCCN treatment regimens for patients with metastatic bladder cancer.
Considering Practice-Changing Maintenance Options in Bladder Cancer
Considering Practice-Changing Maintenance Options in Bladder Cancer
September 25, 2025
Petros Grivas, MD, PhD, discusses how the JAVELIN Bladder 100 trial established avelumab as standard maintenance therapy for advanced bladder cancer.
Advertisement
Advertisement
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • Editorial Board
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us